Pierre Fabre Medicament of France and Zambon S.p.A. of Italy have successfully executed an agreement, signed February 15, 2007, giving Pierre Fabre commercial rights to Zambon’s product portfolio in Germany. 

The strategic partnership involves multiple products, including Panotile Cipro (anti-infective), Fluimicil (mucolytic), Monuril and Lorafem (antibiotics). Also, Pierre Fabre will retain Zambon’s medical sales force in Germany to strengthen its network in the country. 

Pierre Fabre Medicament retained Plexus Ventures, a pharmaceutical business development firm, to assist with the company’s in-licensing and acquisition campaign in Germany. The Plexus Ven-tures team was led by Mr. Pino Modica, managing partner, and success of the project is attributed to the knowledge of senior consultants, Mr. Klaus Welzel in Frankfurt and Mr. Valerio Zoja in Milan.

“One of the main advantages Plexus Ventures brings to our clients is our strong international presence and extensive contacts within the most important markets in the pharmaceutical industry,” noted Pino Modica. “In this case, we were able use our network of contacts to bring new opportunities to the table. We are proud we were able to meet our client’s needs by finding an ideal partner and a deal structure that will benefit both parties in the long run.”

Mr. Alain Benoit, vice president of corporate licensing and acquisitions for Pierre Fabre, said, “We knew that this was a difficult task and we are glad Plexus Ventures was able to help us  achieve this important strategic objective of consolidating our presence in the German market.”